These aforementioned findings provide a new direction for the clinical use of ZXF1 as a biomarker to predict the occurrence and development of EEC, as a valuable factor to determine the survival prognosis of patients, and as a sensitive therapeutic target in endometrial cancer. This evidence concerns the gene ACTA2-AS1 and endometrial cancer.